FY2025 EPS Estimates for Integer Decreased by Zacks Research

Integer Holdings Co. (NYSE:ITGR) – Analysts at Zacks Research decreased their FY2025 EPS estimates for Integer in a research note issued on Tuesday, October 22nd. Zacks Research analyst D. Dey now expects that the medical equipment provider will post earnings per share of $6.03 for the year, down from their prior estimate of $6.04. The consensus estimate for Integer’s current full-year earnings is $5.30 per share. Zacks Research also issued estimates for Integer’s Q1 2026 earnings at $1.64 EPS, Q3 2026 earnings at $1.66 EPS and FY2026 earnings at $6.68 EPS.

Integer (NYSE:ITGR) last issued its earnings results on Thursday, July 25th. The medical equipment provider reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.06. The company had revenue of $436.20 million for the quarter, compared to analysts’ expectations of $437.00 million. Integer had a return on equity of 11.48% and a net margin of 6.31%. Integer’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period last year, the business earned $1.14 EPS.

ITGR has been the subject of a number of other research reports. Benchmark lifted their price target on Integer from $130.00 to $140.00 and gave the company a “buy” rating in a research note on Monday. KeyCorp upped their price target on Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. Truist Financial increased their price target on Integer from $145.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Citigroup lifted their price objective on shares of Integer from $124.00 to $130.00 and gave the stock a “neutral” rating in a report on Tuesday, October 1st. Finally, Bank of America upped their target price on shares of Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $140.14.

Integer Stock Down 1.7 %

Shares of NYSE ITGR opened at $125.58 on Wednesday. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.29 and a quick ratio of 1.96. Integer has a 1 year low of $69.40 and a 1 year high of $133.53. The stock has a market capitalization of $4.21 billion, a P/E ratio of 43.45, a P/E/G ratio of 1.86 and a beta of 1.08. The company has a 50-day moving average price of $127.19 and a 200-day moving average price of $120.82.

Institutional Investors Weigh In On Integer

A number of institutional investors and hedge funds have recently bought and sold shares of ITGR. Quadrature Capital Ltd bought a new position in shares of Integer during the 4th quarter valued at about $378,000. Guidance Capital Inc. purchased a new position in shares of Integer during the first quarter worth approximately $500,000. Congress Wealth Management LLC DE lifted its holdings in shares of Integer by 7.6% in the 1st quarter. Congress Wealth Management LLC DE now owns 69,328 shares of the medical equipment provider’s stock worth $8,089,000 after acquiring an additional 4,873 shares during the last quarter. AlphaMark Advisors LLC purchased a new stake in shares of Integer in the 1st quarter valued at $359,000. Finally, Tributary Capital Management LLC grew its holdings in shares of Integer by 1.2% during the 1st quarter. Tributary Capital Management LLC now owns 285,677 shares of the medical equipment provider’s stock valued at $33,333,000 after purchasing an additional 3,513 shares during the last quarter. 99.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Jean M. Hobby sold 11,960 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $119.66, for a total value of $1,431,133.60. Following the sale, the director now owns 2,280 shares in the company, valued at approximately $272,824.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 2.00% of the stock is owned by insiders.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.